Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases

Correspondence to Professor Kenneth GC Smith; kgcs2@cam.ac.uk ABSTRACT Objectives: Type 1 interferons (IFN-1) are implicated in the pathogenesis of systemic lupus erythematosus (SLE), but most studies have only reported the effect of IFN-1 on mixed cell populations. We aimed to define modules of IFN-1-associated genes in purified leucocyte populations and use these as a basis for a detailed comparative analysis. Methods: CD4+ and CD8+ T cells, monocytes and neutrophils were purified from patients with SLE, other immune-mediated diseases and healthy volunteers and gene expression then determined by microarray. Modules of IFN-1-associated genes were defined using weighted gene coexpression network analysis. The composition and expression of these modules was analysed. Results: 1150 of 1288 IFN-1-associated genes were specific to myeloid subsets, compared with 11 genes unique to T cells. IFN-1 genes were more highly expressed in myeloid subsets compared with T cells. A subset of neutrophil samples from healthy volunteers (HV) and conditions not classically associated with IFN-1 signatures displayed increased IFN-1 gene expression, whereas upregulation of IFN-1-associated genes in T cells was restricted to SLE. Conclusions: Given the broad upregulation of IFN-1 genes in neutrophils including in some HV, investigators reporting IFN-1 signatures on the basis of whole blood samples should be cautious about interpreting this as evidence of bona fide IFN-1mediated pathology. Instead, specific upregulation of IFN-1-associated genes in T cells may be a useful biomarker and a further mechanism by which elevated IFN-1 contributes to autoimmunity in SLE.

[1]  Shruti Sharma,et al.  Widely divergent transcriptional patterns between SLE patients of different ancestral backgrounds in sorted immune cell populations. , 2015, Journal of autoimmunity.

[2]  Kenneth G. C. Smith,et al.  The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE. , 2015, Current pharmaceutical design.

[3]  Virginia Pascual,et al.  Modular Transcriptional Repertoire Analyses of Adults With Systemic Lupus Erythematosus Reveal Distinct Type I and Type II Interferon Signatures , 2014, Arthritis & rheumatology.

[4]  Oliver S. Burren,et al.  A Type I Interferon Transcriptional Signature Precedes Autoimmunity in Children Genetically at Risk for Type 1 Diabetes , 2014, Diabetes.

[5]  Andreas Radbruch,et al.  Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference? , 2013, PloS one.

[6]  D. Absher,et al.  Genome-Wide DNA Methylation Analysis of Systemic Lupus Erythematosus Reveals Persistent Hypomethylation of Interferon Genes and Compositional Changes to CD4+ T-cell Populations , 2013, PLoS genetics.

[7]  L. Davis,et al.  SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature , 2013, PloS one.

[8]  K. Elkon,et al.  Type I IFN system in the development and manifestations of SLE , 2012, Current opinion in rheumatology.

[9]  A. Zychlinsky,et al.  Neutrophil function: from mechanisms to disease. , 2012, Annual review of immunology.

[10]  D. Levy,et al.  Constitutive type I interferon modulates homeostatic balance through tonic signaling. , 2012, Immunity.

[11]  A. Oxenius,et al.  Type‐I IFN drives the differentiation of short‐lived effector CD8+ T cells in vivo , 2012, European journal of immunology.

[12]  Alvis Brazma,et al.  A CD8 T cell transcription signature predicts prognosis in autoimmune disease , 2010, Nature Medicine.

[13]  Yihong Yao,et al.  Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus , 2009, Human genomics and proteomics : HGP.

[14]  Kenneth G. C. Smith,et al.  Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis , 2009, Annals of the rheumatic diseases.

[15]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[16]  R J Falk,et al.  Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. , 2007, Kidney international.

[17]  D. Sehy,et al.  Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. , 2006, Cytokine.

[18]  A. Bertoletti,et al.  Type I IFN Negatively Regulates CD8+ T Cell Responses through IL-10-Producing CD4+ T Regulatory 1 Cells1 , 2005, The Journal of Immunology.

[19]  Ion Gresser,et al.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation. , 2002, Blood.

[20]  G. V. van Seventer,et al.  Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. , 1998, Journal of immunology.

[21]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[22]  H. L. Wright,et al.  Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. , 2015, Rheumatology.